Tuesday, November 5, 2024
HomeNewsSouth Korean Startup Raises $4.2 million To Test Its Digital Therapy For...

South Korean Startup Raises $4.2 million To Test Its Digital Therapy For Neurological Disorders

Nunaps to Test Its Digital Therapeutics for Neurological Disorders

After launching the first digital therapeutic clinical trial in the country, a South Korean startup has raised about $4.2 million to develop and test its software-based treatments for neurological disorders

Their first product ‘Nunap Vision’ provides perception training using a virtual reality headset to help treat visual field defects caused by brain damage, such as from strokes. Currently, the Seoul- based Nunaps is planning to build its first platform.

According to Kang-Soo Lee, chief information officer of Company K Partners, Nunaps has great potential to become a global top-tier. Nunaps is setting up the clinical trials to test its digital therapeutics that use AI to treat neurological disorders. Nunap’s series A round was backed by Company K Partners along with K2 Investment and KTB Network  Partners.

One among five people who have had a stroke is likely to be affected by some sort of vision impairment. They could also lose part of their field of view. According to the company, Nunap Vision is based on the concept that even after vision impairments, some visual stimuli are still transmitted to various parts of the brain and that repeated training can help develop new visual pathways.

To date, there were no reliable treatments for patients with visual field defects. Nunaps founder and CEO Dong-Wha Kang said; “In our efforts to treat patients with unmet needs, we naturally came up with digital.

The rest of the company consist of engineers, neurologists, perceptual psychologists as well as software and game developers and artificial intelligence scientists.

Nunaps is planning to become a leading digital therapeutics platform company in the next few years by developing pipelines for various brain disorders. “It is vital to carry out patient-centered R&D for the developed products to be put into practical use.” Dong-Wha Kang added, “We will develop super-customized digital therapeutics so that patients may directly experience our products and be empowered to engage in our development.

Nunaps to test its digital therapeutics – Source

Author : Namitha Thampi

Shekhar
Shekhar
Shekhar Suman is the Co-founder of BioTecNika Info Labs Pvt. Ltd. He is an Entrepreneur, Writer, Public Speaker, and a Motivational Coach. In his career, he has mentored more than 100,000+ students toward success in the Biopharma Industry. He heads the BioTecNika Group, which comprises BioTecNika.com, BioTecNika.org, and Rasayanika.com. An avid reader and listener who is passionate about BioSciences. Today Biotecnika is India's largest Biotech Career portal, with over 5 Million subscribers from academia & Industry. It's ranked among the top 50 websites worldwide in the Biology category.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments

Aarati Bhirwandekar 9967415389 on Amgen Biotech Jobs – Scientist Post Vacancy